Progyny (NASDAQ:PGNY) Shares Gap Down – What’s Next?

Progyny, Inc. (NASDAQ:PGNY) shares gapped down before the market opened on Friday . The stock had previously closed at $30.21, but opened at $25.56. Progyny shares last traded at $27.7760, with a volume of 452,256 shares traded.

Key Progyny News

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported adjusted earnings of $0.55 per share, above estimates ranging from $0.33 to $0.51 and up from $0.19 in the year-ago quarter. Revenue rose 5.3% year over year to $350.5 million, slightly exceeding the $348.6 million consensus estimate. Progyny, Inc. Announces Second Quarter 2026 Results
• Positive Sentiment: Management issued full-year 2026 EPS guidance of $2.04 to $2.10, above the roughly $1.86 analyst consensus. The outlook indicates stronger profitability than Wall Street had expected. Progyny Q2 Earnings and Revenues Beat Estimates
• Neutral Sentiment: Full-year revenue guidance was maintained at approximately $1.4 billion, broadly in line with analyst expectations. The earnings presentation and call provided additional detail on the quarter and outlook, but the reported figures remain the primary catalyst for investors. Progyny 2026 Q2 Results Earnings Call Presentation
• Negative Sentiment: Third-quarter revenue guidance of $335 million to $345 million fell below the approximately $350.2 million consensus estimate, even though projected EPS of $0.50 to $0.52 exceeded the $0.47 estimate. The revenue shortfall likely raised concerns about client growth and near-term demand momentum. Progyny Reports Q2 Earnings: Key Metrics
• Negative Sentiment: The market reaction suggests investors placed greater emphasis on the below-consensus third-quarter revenue outlook and only 5.3% year-over-year quarterly revenue growth than on the earnings beat and improved full-year EPS guidance. Progyny Q2 Results and Stock Reaction

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Citizens Jmp increased their target price on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research note on Monday, May 11th. Citigroup restated an “outperform” rating on shares of Progyny in a report on Monday, May 11th. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 8th. KeyCorp boosted their price target on shares of Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Finally, Leerink Partners set a $38.00 price target on shares of Progyny in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Progyny presently has an average rating of “Moderate Buy” and a consensus price target of $33.17.

Progyny Price Performance

The company’s 50 day simple moving average is $29.02 and its 200 day simple moving average is $23.40. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of 37.81, a P/E/G ratio of 2.49 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The business had revenue of $350.51 million for the quarter, compared to analyst estimates of $348.63 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, analysts forecast that Progyny, Inc. will post 1.19 earnings per share for the current year.

Progyny announced that its Board of Directors has authorized a stock buyback program on Tuesday, May 26th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 10.3% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling

In other news, Director Kevin K. Gordon sold 5,500 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $24.99, for a total transaction of $137,445.00. Following the completion of the transaction, the director directly owned 9,318 shares of the company’s stock, valued at approximately $232,856.82. The trade was a 37.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Allison Swartz sold 1,199 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $25.02, for a total transaction of $29,998.98. Following the sale, the executive vice president owned 83,316 shares in the company, valued at $2,084,566.32. The trade was a 1.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 36,916 shares of company stock worth $939,875 over the last ninety days. Company insiders own 9.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PGNY. Easterly Investment Partners LLC grew its stake in Progyny by 197.4% during the 4th quarter. Easterly Investment Partners LLC now owns 146,013 shares of the company’s stock worth $3,750,000 after buying an additional 96,912 shares during the last quarter. First Eagle Investment Management LLC lifted its stake in Progyny by 40.2% in the fourth quarter. First Eagle Investment Management LLC now owns 212,612 shares of the company’s stock valued at $5,460,000 after buying an additional 60,912 shares during the last quarter. Simcoe Capital LLC acquired a new stake in shares of Progyny in the fourth quarter valued at approximately $3,902,000. CenterBook Partners LP boosted its holdings in shares of Progyny by 36.2% in the fourth quarter. CenterBook Partners LP now owns 578,171 shares of the company’s stock valued at $14,847,000 after acquiring an additional 153,778 shares during the period. Finally, SG Americas Securities LLC grew its position in shares of Progyny by 225.3% during the first quarter. SG Americas Securities LLC now owns 61,391 shares of the company’s stock worth $1,042,000 after acquiring an additional 42,520 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.